Zydus Lifesciences’ Assertio merger signals a bigger push beyond generics into U.S. oncology
Find out how Zydus Lifesciences’ Assertio merger could reshape its U.S. oncology supportive-care strategy and Rolvedon growth.
Pharma & Biotech
Pharma & Biotech
Zydus gains FDA Priority Review for saroglitazar as PBC treatment competition intensifies
Zydus’ saroglitazar gets FDA Priority Review in PBC, setting up a key test for dual PPAR therapy in rare liver disease.